BIOR Key Statistics, Chart & Performance
The current stock price of BIOR is 0.5597 USD. In the past month the price decreased by -79.42%. In the past year, price decreased by -95.88%.
BIOR Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.44 | 391.56B | ||
| AMGN | AMGEN INC | 14.94 | 175.99B | ||
| GILD | GILEAD SCIENCES INC | 14.82 | 150.63B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.87 | 118.34B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.21 | 81.43B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 778.1 | 52.43B | ||
| INSM | INSMED INC | N/A | 37.13B | ||
| NTRA | NATERA INC | N/A | 33.75B | ||
| BIIB | BIOGEN INC | 10.78 | 26.47B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.12 | 21.73B | ||
| INCY | INCYTE CORP | 16.53 | 20.84B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.29B |
Related stock screener links
About BIOR
Company Profile
Biora Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 58 full-time employees. The company went IPO on 2020-06-19. Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. The company has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.
Company Info
BIORA THERAPEUTICS INC
4330 La Jolla Village Drive, Suite 200
San Diego CALIFORNIA US
Employees: 58
Phone: 18552932639
BIORA THERAPEUTICS INC / BIOR FAQ
What does BIOR do?
Biora Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in San Diego, California and currently employs 58 full-time employees. The company went IPO on 2020-06-19. Biora Therapeutics, Inc. is a biotechnology company, which is focused on creating smart pills designed for targeted drug delivery to the gastrointestinal (GI) tract, and systemic, needle-free delivery of biotherapeutics. The Company’s pipeline includes two therapeutic delivery platforms: NaviCap and BioJet. The NaviCap, targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract. The BioJet, systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules. The company has two demonstration drug-device combination programs for the BioJet platform, BT-200 (GLP-1 receptor agonist) and BT-002 (adalimumab variant). Its other two programs include BT-600 (NaviCap + tofacitinib) and BT-001 (NaviCap + variant of adalimumab) for the treatment of ulcerative colitis.
What is the stock price of BIORA THERAPEUTICS INC today?
The current stock price of BIOR is 0.5597 USD. The price decreased by -58.54% in the last trading session.
Does BIOR stock pay dividends?
BIOR does not pay a dividend.
How is the ChartMill rating for BIORA THERAPEUTICS INC?
BIOR has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What sector and industry does BIORA THERAPEUTICS INC belong to?
BIORA THERAPEUTICS INC (BIOR) operates in the Health Care sector and the Biotechnology industry.
Is BIORA THERAPEUTICS INC (BIOR) expected to grow?
The Revenue of BIORA THERAPEUTICS INC (BIOR) is expected to grow by 39100% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is BIORA THERAPEUTICS INC worth?
BIORA THERAPEUTICS INC (BIOR) has a market capitalization of 2.53M USD. This makes BIOR a Nano Cap stock.
BIOR Technical Analysis
BIOR Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to BIOR. Both the profitability and financial health of BIOR have multiple concerns.
BIOR Financial Highlights
Over the last trailing twelve months BIOR reported a non-GAAP Earnings per Share(EPS) of -10.84. The EPS decreased by -22.72% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -217.44% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
BIOR Forecast & Estimates
7 analysts have analysed BIOR and the average price target is 34.68 USD. This implies a price increase of 6096.18% is expected in the next year compared to the current price of 0.5597.
For the next year, analysts expect an EPS growth of 88.79% and a revenue growth 39100% for BIOR